Mirae Asset Global Investments’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $303K | Sell |
3,710
-607
| -14% | -$43.8K | ﹤0.01% | 1060 |
|
|
2026
Q1 | $294K | Buy |
4,317
+416
| +11% | +$29.5K | ﹤0.01% | 1019 |
|
|
2025
Q4 | $296K | Buy |
3,901
+830
| +27% | +$60.3K | ﹤0.01% | 1093 |
|
|
2025
Q3 | $188K | Buy |
3,071
+9
| +0.3% | +$469 | ﹤0.01% | 1132 |
|
|
2025
Q2 | $150K | Buy |
3,062
+423
| +16% | +$20.1K | ﹤0.01% | 1084 |
|
|
2025
Q1 | $143K | Buy |
2,639
+69
| +3% | +$3.44K | ﹤0.01% | 1087 |
|
|
2024
Q4 | $116K | Sell |
2,570
-212
| -8% | -$9.07K | ﹤0.01% | 1124 |
|
|
2024
Q3 | $104K | Buy |
2,782
+492
| +21% | +$16.5K | ﹤0.01% | 1180 |
|
|
2024
Q2 | $79.4K | Sell |
2,290
-39,401
| -95% | -$1.28M | ﹤0.01% | 1172 |
|
|
2024
Q1 | $1.7M | Sell |
41,691
-4,078
| -9% | -$114K | ﹤0.01% | 1280 |
|
|
2023
Q4 | $1.26M | Buy |
45,769
+6,335
| +16% | +$145K | ﹤0.01% | 1495 |
|
|
2023
Q3 | $884K | Buy |
39,434
+122
| +0.3% | +$4.54K | ﹤0.01% | 1577 |
|
|
2023
Q2 | $1.6M | Buy |
39,312
+1,139
| +3% | +$55.7K | ﹤0.01% | 1323 |
|
|
2023
Q1 | $1.85M | Buy |
38,173
+5,829
| +18% | +$266K | ﹤0.01% | 1247 |
|
|
2022
Q4 | $1.23M | Buy |
32,344
+965
| +3% | +$40.1K | ﹤0.01% | 1376 |
|
|
2022
Q3 | $1.58M | Buy |
31,379
+8,975
| +40% | +$440K | ﹤0.01% | 1253 |
|
|
2022
Q2 | $898K | Buy |
+22,404
| New | +$786K | ﹤0.01% | 1452 |
|
|
2021
Q2 | – | Sell |
-129,565
| Closed | -$6.13M | – | 1729 |
|
|
2021
Q1 | $6.13M | Buy |
129,565
+59,345
| +85% | +$3.52M | 0.02% | 692 |
|
|
2020
Q4 | $4.29M | Buy |
70,220
+29,355
| +72% | +$1.73M | 0.02% | 687 |
|
|
2020
Q3 | $1.91M | Buy |
40,865
+12,888
| +46% | +$635K | 0.01% | 792 |
|
|
2020
Q2 | $1.42M | Buy |
27,977
+5,540
| +25% | +$272K | 0.01% | 797 |
|
|
2020
Q1 | $1M | Buy |
22,437
+2,445
| +12% | +$123K | 0.01% | 822 |
|
|
2019
Q4 | $960K | Buy |
19,992
+1,350
| +7% | +$57.4K | 0.01% | 975 |
|
|
2019
Q3 | $630K | Buy |
18,642
+13,255
| +246% | +$577K | ﹤0.01% | 1082 |
|
|
2019
Q2 | $242K | Buy |
+5,387
| New | +$213K | ﹤0.01% | 1328 |
|
|
2019
Q1 | – | Sell |
-37,036
| Closed | -$1.27M | – | 1344 |
|
|
2018
Q4 | $1.27M | Buy |
37,036
+5,036
| +16% | +$181K | 0.01% | 716 |
|
|
2018
Q3 | $1.5M | Buy |
+32,000
| New | +$1.32M | 0.01% | 726 |
|
|
2015
Q4 | – | Sell |
-57,358
| Closed | -$1.53M | – | 475 |
|
|
2015
Q3 | $1.53M | Buy |
57,358
+19,670
| +52% | +$841K | 0.06% | 240 |
|
|
2015
Q2 | $1.81M | Buy |
+37,688
| New | +$2.2M | 0.06% | 222 |
|
Other funds holding PTCT
RI
JT
Mirae Asset Global Investments's PTCT Position: Q2 2026 in Review
Mirae Asset Global Investments reduced its PTC Therapeutics (PTCT) stake by 14% in Q2 2026, selling an estimated $43.8K and leaving 3,710 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1060.
Mirae Asset Global Investments first reported a position in PTCT in Q2 2015 and has held it in 29 quarters since. The position peaked at $6.13M in Q1 2021. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Mirae Asset Global Investments held 3,710 shares of PTC Therapeutics worth $303K as of Q2 2026.
- Mirae Asset Global Investments sold 607 PTC Therapeutics shares in Q2 2026, an estimated $43.8K.
- PTC Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1060 holding.
- Mirae Asset Global Investments first reported a position in PTC Therapeutics in Q2 2015 and has held it in 29 quarters since.
- Mirae Asset Global Investments's PTC Therapeutics position peaked at $6.13M in Q1 2021.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.